PMID- 23530859
OWN - NLM
STAT- MEDLINE
DCOM- 20140210
LR  - 20211021
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Print)
IS  - 1937-3341 (Linking)
VI  - 19
IP  - 15-16
DP  - 2013 Aug
TI  - Nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and 
      glial-derived neurotrophic factor enhance angiogenesis in a tissue-engineered in 
      vitro model.
PG  - 1655-64
LID - 10.1089/ten.tea.2012.0745 [doi]
AB  - Skin is a major source of secretion of the neurotrophic factors nerve growth 
      factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
      and glial-derived neurotrophic factor (GDNF) controlling cutaneous sensory 
      innervation. Beside their neuronal contribution, we hypothesized that 
      neurotrophic factors also modulate the cutaneous microvascular network. First, we 
      showed that NGF, BDNF, NT-3, and GDNF were all expressed in the epidermis, while 
      only NGF and NT-3 were expressed by cultured fibroblasts, and BDNF by human 
      endothelial cells. We demonstrated that these peptides are highly potent 
      angiogenic factors using a human tissue-engineered angiogenesis model. A 40% to 
      80% increase in the number of capillary-like tubes was observed after the 
      addition of 10 ng/mL of NGF, 0.1 ng/mL of BDNF, 15 ng/mL of NT-3, and 50 ng/mL of 
      GDNF. This is the first characterization of the direct angiogenic effect of NT-3 
      and GDNF. This angiogenic effect was mediated directly through binding with the 
      neurotrophic factor receptors tropomyosin-receptor kinase A (TrkA), TrkB, GFRalpha-1 
      and c-ret that were all expressed by human endothelial cells, while this effect 
      was blocked by addition of the Trk inhibitor K252a. Thus, if NGF, BDNF, NT-3, and 
      GDNF may only moderately regulate the microvascular network in normal skin, they 
      might have the potential to greatly increase angiogenesis in pathological 
      situations.
FAU - Blais, Mathieu
AU  - Blais M
AD  - Departement de Chirurgie, Faculte de Medecine, Centre LOEX de l'Universite Laval, 
      Centre de recherche du CHU de Quebec, Universite Laval, Quebec, Canada.
FAU - Levesque, Philippe
AU  - Levesque P
FAU - Bellenfant, Sabrina
AU  - Bellenfant S
FAU - Berthod, Francois
AU  - Berthod F
LA  - eng
GR  - MOP-106429/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130326
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Glial Cell Line-Derived Neurotrophic Factor)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Neurotrophin 3)
SB  - IM
MH  - Brain-Derived Neurotrophic Factor/*pharmacology
MH  - Cells, Cultured
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fibroblasts
MH  - Fluorescent Antibody Technique, Indirect
MH  - Glial Cell Line-Derived Neurotrophic Factor/*pharmacology
MH  - Humans
MH  - Neovascularization, Physiologic/*drug effects
MH  - Nerve Growth Factors/*pharmacology
MH  - Neurotrophin 3/*pharmacology
MH  - Tissue Engineering
PMC - PMC3700174
EDAT- 2013/03/28 06:00
MHDA- 2014/02/11 06:00
PMCR- 2014/08/01
CRDT- 2013/03/28 06:00
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2014/02/11 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - 10.1089/ten.tea.2012.0745 [pii]
AID - 10.1089/ten.tea.2012.0745 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2013 Aug;19(15-16):1655-64. doi: 10.1089/ten.tea.2012.0745. 
      Epub 2013 Mar 26.